SHARON, Pa., Aug. 12 /PRNewswire-FirstCall/ -- NanoLogix, Inc.,
(Pink Sheets: NNLX), a Nano-biotechnology company engaged in the research,
development and commercialization of technologies for alternative sources of
fuel, the production of bacteria and disease testing kits, cancer therapy and
remediation of toxic materials announced today that the recent signing of the
energy bill, passed by Congress and signed by the President, should provide an
opportunity for NanoLogix to demonstrate its recent developments in hydrogen
generation systems.
NanoLogix's recent agreement to generate hydrogen from a NanoLogix
scale-up bioreactor system using Arrowhead Wine Cellar's waste organic matter
is the company's first scale-up unit installation providing valuable data for
engineered systems.
The signing of the bill helps companies like NanoLogix diversify our
national energy supply by promoting alternative and renewable energy sources.
Hydrogen, which is clean burning, has great potential in hydrogen-powered
automobiles, industrial and other uses toward a more affordable and reliable
energy future for everyone.
The production of hydrogen is an increasingly common and important
procedure in the world today. Production of hydrogen in the U.S. alone
currently amounts to about 3 billion cubic feet per year, with output likely
to increase. Uses for the produced hydrogen are varied, ranging from uses in
welding, in production of hydrochloric acid, and for reduction of metallic
ores. An increasingly important use of hydrogen, however, is in the
production of alternative fuels for machinery, such as motor vehicles.
Successful use of hydrogen as an alternative fuel can provide substantial
benefits to the world at large. This is important not only in that hydrogen
can be formed without dependence on the location of specific oils or other
ground resources, but in that burning of hydrogen for fuel is atmospherically
clean. Essentially, no carbon dioxide or greenhouse gasses are produced.
Thus, production of hydrogen as a fuel source can have great impact on the
world at large.
About NanoLogix
NanoLogix, Inc., formerly known as Infectech, Inc.
( http://www.infectech.com ), is a technology application innovator of biogas
products and services designed to assist in worldwide energy independence and
reduce pollution from renewable, environmentally-friendly energy sources.
NanoLogix is also engaged in diagnostic test kits designed to be used for the
rapid identification of infectious human diseases. The Company's patents span
the identification and antibiotic sensitivity testing of 34 disease-producing
bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare
(MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes
of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS.
Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis
in cancer cells utilizing hydrophobic hydrocarbons.
This press release contains statements, which may constitute "forward-
looking statements" within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements regarding
the intent, belief or current expectations of NanoLogix, Inc., and members of
its management as well as the assumptions on which such statements are based.
Prospective investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and uncertainties,
and that actual results may differ materially from those contemplated by such
forward-looking statements. Important factors currently known to management
that could cause actual results to differ materially from those in forward-
statements include fluctuation of operating results, the ability to compete
successfully and the ability to complete before-mentioned transactions. The
company undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of unanticipated
events or changes to future operating results.
SOURCE NanoLogix, Inc.
 back to top
Related links:
http://www.infectech.com
http://www.nanologix.net
CONTACT:
PR Department of NanoLogix, Inc.,
+1-724-346-1302
|
